BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Danish pharma company Bavarian Nordic is shutting down its U.S.-based R&D site in San Diego and laying off all 48 employees ...